Core Insights - Clearside Biomedical is focused on the potential of suprachoroidal drug delivery, positioning itself as a leader in this innovative space with a proprietary SCS Microinjector that has been validated through numerous clinical injections [7][10][37] - The company has developed the first FDA-approved product for suprachoroidal administration, XIPERE, which is currently being commercialized in the U.S. and is seeking approval in Canada and Australia [12][37] - The pipeline includes CLS-AX, a tyrosine kinase inhibitor for wet AMD, which is completing Phase IIb trials, with data expected in late Q3 2024 [8][11][56] Company Overview - Clearside Biomedical has established multiple strategic collaborations to enhance its capabilities in the suprachoroidal space, including partnerships with Aura, REGENXBIO, AbbVie, and BioCryst [13][14] - The company has a comprehensive intellectual property portfolio surrounding its microinjector platform, which supports various drug categories for retinal diseases [7][10] Product Development - The SCS Microinjector has been used in over 10,000 injections without reported cases of endophthalmitis, indicating a favorable safety profile compared to traditional intravitreal injections [40] - XIPERE has shown promising real-world efficacy, with approximately 86.5% of patients not requiring rescue therapy within six months, comparable to clinical trial results [30][37] Market Potential - The market for geographic atrophy is considered larger than that for wet AMD, with ongoing research into improving treatment efficacy and duration [58] - The company aims to leverage its expertise in suprachoroidal delivery to develop therapies targeting geographic atrophy, which is increasingly recognized as a choroidal disease [62][66] Future Outlook - Clearside Biomedical plans to initiate a Phase III study for CLS-AX, which is expected to provide data that could facilitate its approval and integration into clinical practice [55][56] - The company is exploring the potential of gene therapy applications through its suprachoroidal delivery system, which may offer advantages over traditional methods [66][68]

The event will include presentations by the following retinal experts concluding with a live question-andanswer session with the KOLs and Clearside senior management: Any statements contained in this press release that do not describe historical facts may constitute forwardlooking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan", "potential", "will", and similar expressions, and ...

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on ...

ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on ...

- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), anno ...

ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced plans to host a virtual key opinion leader (KOL) event on Wednesday, July 24, 2024 from 8:00 - 9:15 am ET. The live and archived webcast will be accessible on the Clearside website under the Investors section: Events and Presentations. - Retina Specialists to Provide Insigh ...

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - "Clearside is leading the way in suprachoroidal delivery, including having the only FDA approved product for suprachoroidal use and a second program with an expected near-term clinical data readout for CLS-AX in the large wet AMD market," said Victor Chong, M.D., MBA, Chief Medical Officer of Clearside. "We believe that suprachoroidal delivery combined with the differentiated mechanism of action and high potency of axi ...

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - Title: Suprachoroidal Drug Delivery in the Real World Presented by: Glenn Yiu , M.D., PhD Summary: Additional Presentations Delivered by Clearside Commercial and Development Partners ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced t ...

The publication, entitled, "Suprachoroidal Space Injection Technique: Expert Panel Guidance" was co-authored by 16 practicing retinal physicians led by Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, Houston, TX. The guidance was developed based on current published evidence and clinical experience. The panel established consensus on the rationale for SCS injection, including potential benefits relative to other intraocular delivery methods, and current best practices in patient preparation, pre- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37783 Clearside Biomedical, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 900 North Po ...